

Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations:

PI Accessory Mutations:

PR Other Mutations:

None

None

L10V 100%
seen=0,100 • I13V 99%
seen=0,100 • K14R 99%
seen=0,101 • G16E 100%
seen=0,100 • L19I 99%
seen=0,100 • K20R 99%
seen=0,101 • E35D 100%
seen=0,100 • M36I 100%
seen=0,100 • R41K 99%
seen=0,100 • R57K 99%
seen=0,101 • L63T 100%
seen=0,100 • H69K 99%
seen=0,101 • L89M 99%
seen=0,100

Protease Inhibitors

atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

PR comments

Other

- L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.
- K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

NNRTI Mutations:

RT Other Mutations:

M184V 99%
seen=0,219

Y188L 99%
seen=0,100

P4S 100%
seen=0,101 • IDV 99%
seen=0,101 • K11A 100%
seen=0,101 • V21I 100%
seen=0,100 • V35T 100%
seen=0,101 • T39R 100%
seen=0,100 • K43R 100%
seen=0,100 • K122E 100%
seen=0,101 • D123N 100%
seen=0,101 • K173L 99%
seen=0,101 • Q174K 99%
seen=0,101 • D177E 99%
seen=0,100 • V179I 100%
seen=0,101 • T200A 100%
seen=0,101 • I202V 100%
seen=0,100 • Q207T 99%
seen=0,100 • R211S 99%
seen=0,100 • V245Q 100%
seen=0,101 • E248D 100%
seen=0,101 • D250S 100%
seen=0,101

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)	Low-Level Resistance
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Potential Low-Level Resistance
emtricitabine (FTC)	High-Level Resistance
lamivudine (3TC)	High-Level Resistance
tenofovir (TDF)	Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)	High-Level Resistance
efavirenz (EFV)	High-Level Resistance
etravirine (ETR)	Potential Low-Level Resistance
nevirapine (NVP)	High-Level Resistance
rilpivirine (RPV)	High-Level Resistance

RT comments

NRTI

- M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

NNRTI

- Y188L is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.

Other

- V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of NRTI:

Download CSV

Rule	ABC	AZT	D4T	DDI	FTC	3TC	TDF
M184V	15	-10	-10	10	60	60	-10

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR	EFV	ETR	NVP	RPV
Y188L	60	60	10	60	60